Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances
暂无分享,去创建一个
Wenfu Xu | Feifang Hu | Siu Hung Cheung | Jingya Gao | F. Hu | Wenfu Xu | Jingya Gao | S. Cheung
[1] Ralph B. D'Agostino,et al. Challenges in the Design and Interpretation of Noninferiority Trials , 2017, The New England journal of medicine.
[2] Feifang Hu,et al. Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials , 2003 .
[3] S. Sundar,et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial , 2011, The Lancet.
[4] William F. Rosenberger,et al. Implementing Optimal Allocation in Sequential Binary Response Experiments , 2007 .
[5] A. Januszewicz,et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial , 2013, Diabetologia.
[6] Sue-Jane Wang,et al. Challenges and regulatory experiences with non-inferiority trial design without placebo arm. , 2009, Biometrical journal. Biometrische Zeitschrift.
[7] W. Rosenberger,et al. The theory of response-adaptive randomization in clinical trials , 2006 .
[8] S. Ellenberg,et al. Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 2: Practical Issues and Specific Cases , 2000, Annals of Internal Medicine.
[9] F. Hu,et al. Adaptive Designs for Non-inferiority Trials with Multiple Experimental Treatments , 2018, Statistical methods in medical research.
[10] Scott M Berry,et al. A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response , 2016, Clinical trials.
[11] William F. Rosenberger,et al. Optimality, Variability, Power , 2003 .
[12] K. Kwong,et al. Testing of non-inferiority and superiority for three-arm clinical studies with multiple experimental treatments , 2018, Statistical methods in medical research.
[13] S. Julious. The ABC of non‐inferiority margin setting from indirect comparisons , 2011, Pharmaceutical statistics.
[14] Ludwig A Hothorn,et al. Multiple Contrast Tests in the Presence of Heteroscedasticity , 2008, Biometrical journal. Biometrische Zeitschrift.
[15] Feifang Hu,et al. ST ] 1 7 O ct 2 00 6 ASYMPTOTIC PROPERTIES OF COVARIATE-ADJUSTED ADAPTIVE DESIGNS , 2006 .
[16] W. Rosenberger,et al. Randomization in Clinical Trials: Theory and Practice , 2002 .
[17] Anne M Wallace,et al. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. , 2016, The New England journal of medicine.
[18] Ajit C. Tamhane,et al. A Comparison of Procedures for Multiple Comparisons of Means with Unequal Variances , 1979 .
[19] R. Bergenstal,et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial , 2010, The Lancet.
[20] M. Abt,et al. Issues in the assessment of non‐inferiority: perspectives drawn from case studies , 2011, Pharmaceutical statistics.
[21] Donald A. Berry,et al. Optimal adaptive randomized designs for clinical trials , 2007 .
[22] Michael Woodroofe,et al. Central Limit Theorems for Doubly Adaptive Biased Coin Designs , 1995 .
[23] Jeffrey R. Eisele. The doubly adaptive biased coin design for sequential clinical trials , 1994 .
[24] G. Vanderstraeten,et al. A multi-center, double-blind, randomized, placebo-controlled trial protocol to assess Traumeel injection vs dexamethasone injection in rotator cuff syndrome: the TRAumeel in ROtator cuff syndrome (TRARO) study protocol , 2015, BMC Musculoskeletal Disorders.
[25] C. Ruckes,et al. Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone , 2014, Addiction.
[26] D. Berry,et al. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. , 1995, Statistics in medicine.
[27] Miin-Jye Wen,et al. Extension of three‐arm non‐inferiority studies to trials with multiple new treatments , 2012, Statistics in medicine.
[28] Li-Xin Zhang,et al. Asymptotic properties of covariate-adjusted response-adaptive designs , 2006 .
[29] S. H. Cheung,et al. Noninferiority Studies with Multiple New Treatments and Heterogeneous Variances , 2015, Journal of biopharmaceutical statistics.
[30] Trudie Lang. Adaptive Trial Design: Could We Use This Approach to Improve Clinical Trials in the Field of Global Health? , 2011, The American journal of tropical medicine and hygiene.
[31] A. Hayter,et al. Step-up procedures for non-inferiority tests with multiple experimental treatments , 2016, Statistical methods in medical research.
[32] C. Montgomery. From Standardization to Adaptation: Clinical Trials and the Moral Economy of Anticipation , 2017 .
[33] H. Valdez,et al. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.
[34] Feifang Hu,et al. Maximizing power and minimizing treatment failures in clinical trials , 2004, Clinical trials.
[35] G. Umpierrez,et al. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5) , 2014, Diabetes Care.
[36] T. Fleming,et al. Issues in noninferiority trials: the evidence in community-acquired pneumonia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.